The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...
As of December 31, 2024, Fortress' consolidated cash and cash equivalents totaled $57.3 million, compared to $58.9 million as ...
Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platformFiled IND in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback